Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors

You may not qualify if:

• Patients who meet any of the following criteria will be not eligible for the study:
• Any treatment specifically for systemic tumor control given within 3 weeks before the initiation of therapy; within 2 weeks if cytotoxic agents were given weekly, within 6 weeks for nitrosoureas or mitomycin C; within 5 half-lives for targeted agents with half-lives and pharmacodynamic effects lasting \< 5 days; or failure to recover from toxic effects of any previous therapy. A drug that has not received regulatory approval for any indication within 14 or 21 days of treatment for a non-myelosuppressive or myelosuppressive agent, respectively: patients must recover for previous cancer therapy, and are ready to proceed with further cancer therapy.
• Uncontrolled intercurrent illness including but not limited to:
• ongoing or active infection requiring intravenous antibiotics
• symptomatic congestive heart failure (New York Heart Association Class III or IV)
• history of myocardial infarction, unstable angina, stroke or transient ischemic attack within 6 months before study enrollment
• lesions invading or encasing any major blood vessels and cavitating pulmonary lesion(s) or known endotracheal or endobronchial disease manifestation. Uncontrolled hypertension defined as sustained blood pressure (BP) \> 140 mm Hg systolic or \> 90 mm Hg diastolic despite optimal antihypertensive treatment (apply to bevacizumab-based regimens only)
• history or current evidence of uncontrolled ventricular arrhythmia
• congenital long QT syndrome, or any known history of torsade de pointes, or family history of unexplained sudden death
• clinically significant bleeding or active gastric or duodenal ulcer
• chronic diarrhea diseases considered to be clinically significant by investigator
• Abdominal fistula, GI perforation, bowel obstruction, or intra-abdominal abscess within 6 months before first dose of study treatment, or any gastrointestinal disorders associated with a high risk of perforation or fistula formation
• other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation, or may interfere with the interpretation of study results, and in the judgment of the Investigator would make the patient inappropriate for entry into this study Note: Subjects with a diagnosis of incidental, subsegmental pulmonary embolism or deep vein thrombosis are allowed if stable, asymptomatic, and treated with a stable dose of permitted anticoagulation for at least 1 week before first dose of study treatment.
• Unresolved clinically significant Grade 1 or higher toxicity from prior therapy.
• History of allergic reactions to the study drugs, or any component of the products.
• +17 more criteria